JPMorgan Downgraded Several Biotech Stocks (ACOR, ALTH, AMAG, AMGN & VPHM)
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $415.21 -0.63%
Rating Summary:
20 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
20 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
JPMorgan downgraded several biotech stocks this morning.
Analyst, Geoffrey Meacham, cut Amgen (Nasdaq: AMGN), ViroPharma (Nasdaq: VPHM), Acorda Therapeutics (Nasdaq: ACOR), and Allos Therapeutics (Nasdaq: ALTH) from 'Overweight' to 'Neutral'.
Meachum also downgraded AMAG Pharmaceuticals (Nasdaq: AMAG) from Neutral to Underweight and slashed its price target from $20 to $12.
Analyst, Geoffrey Meacham, cut Amgen (Nasdaq: AMGN), ViroPharma (Nasdaq: VPHM), Acorda Therapeutics (Nasdaq: ACOR), and Allos Therapeutics (Nasdaq: ALTH) from 'Overweight' to 'Neutral'.
Meachum also downgraded AMAG Pharmaceuticals (Nasdaq: AMAG) from Neutral to Underweight and slashed its price target from $20 to $12.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
- DA Davidson Downgrades Blaize Inc. (BZAI) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
